Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer.

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR.

Transl Oncol. 2019 Aug;12(8):1038-1044. doi: 10.1016/j.tranon.2019.04.014. Epub 2019 May 27.

2.

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer.

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH.

BMC Cancer. 2019 May 23;19(1):488. doi: 10.1186/s12885-019-5724-z.

3.

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM.

Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13.

4.

Comparison of Intravoxel incoherent motion imaging and multiecho dynamic contrast-based MRI in rectal cancer.

Bakke KM, Grøvik E, Meltzer S, Negård A, Holmedal SH, Mikalsen LTG, Lyckander LG, Ree AH, Gjesdal KI, Redalen KR, Bjørnerud A.

J Magn Reson Imaging. 2019 Oct;50(4):1114-1124. doi: 10.1002/jmri.26740. Epub 2019 Apr 4.

5.

Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM.

Cancer Immunol Res. 2019 May;7(5):701-706. doi: 10.1158/2326-6066.CIR-18-0777. Epub 2019 Feb 25.

PMID:
30804006
6.

An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer.

Bjørnetrø T, Redalen KR, Meltzer S, Thusyanthan NS, Samiappan R, Jegerschöld C, Handeland KR, Ree AH.

J Extracell Vesicles. 2019 Jan 29;8(1):1567219. doi: 10.1080/20013078.2019.1567219. eCollection 2019.

7.

Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer.

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH.

Transl Oncol. 2019 Jan;12(1):76-83. doi: 10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29.

8.

Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer.

Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL.

Clin Chim Acta. 2018 Dec;487:107-111. doi: 10.1016/j.cca.2018.09.029. Epub 2018 Sep 18.

PMID:
30240586
9.

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH.

Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26.

10.

Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis.

Gopinathan U, Redalen KR, Trøseid AM, Kierulf P, Brandtzaeg P, Ree AH, Berg JP, Øvstebø R.

PLoS One. 2018 Jan 19;13(1):e0181912. doi: 10.1371/journal.pone.0181912. eCollection 2018.

11.

Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.

Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T.

J Am Heart Assoc. 2017 Nov 8;6(11). pii: e006513. doi: 10.1161/JAHA.117.006513.

12.

Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial.

Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T.

Eur Heart J Cardiovasc Imaging. 2018 May 1;19(5):544-552. doi: 10.1093/ehjci/jex159.

PMID:
29106497
13.

Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K.

Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29.

14.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

15.

Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival.

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR.

Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17.

PMID:
28464745
16.

Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor Ktrans and ΔR2* peak are significantly associated with lymph node metastasis.

Grøvik E, Redalen KR, Storås TH, Negård A, Holmedal SH, Ree AH, Meltzer S, Bjørnerud A, Gjesdal KI.

J Magn Reson Imaging. 2017 Jul;46(1):194-206. doi: 10.1002/jmri.25566. Epub 2016 Dec 21.

PMID:
28001320
17.

Immune-modulating cancer therapy - back to the future.

Ree AH.

Tidsskr Nor Laegeforen. 2016 Oct 25;136(19):1605. eCollection 2016 Oct. English, Norwegian. No abstract available.

18.

Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H.

Br J Cancer. 2016 Oct 11;115(8):929-939. doi: 10.1038/bjc.2016.278. Epub 2016 Sep 6.

19.

Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH.

Cancer Res Treat. 2017 Apr;49(2):374-386. doi: 10.4143/crt.2016.080. Epub 2016 Jul 28.

20.

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH.

BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x.

21.

Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.

Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.

BMC Cancer. 2016 Jul 26;16:531. doi: 10.1186/s12885-016-2600-y.

22.

Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH.

Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995.

23.

Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH.

Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8.

PMID:
26968754
24.

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T.

Eur Heart J. 2016 Jun 1;37(21):1671-80. doi: 10.1093/eurheartj/ehw022. Epub 2016 Feb 21.

25.

Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):532-9. doi: 10.1016/j.clon.2016.01.014. Epub 2016 Feb 14.

PMID:
26888115
26.

High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T.

Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17.

27.

Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.

Hektoen HH, Ree AH, Redalen KR, Flatmark K.

J Enzyme Inhib Med Chem. 2016 Oct;31(5):779-86. doi: 10.3109/14756366.2015.1069286. Epub 2015 Aug 5.

PMID:
26244271
28.

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH.

BMC Cancer. 2015 Jul 24;15:543. doi: 10.1186/s12885-015-1557-6.

29.

Personalized radiotherapy: concepts, biomarkers and trial design.

Ree AH, Redalen KR.

Br J Radiol. 2015 Jul;88(1051):20150009. doi: 10.1259/bjr.20150009. Epub 2015 May 20. Review.

30.

MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR.

Br J Radiol. 2015 Jul;88(1051):20150097. doi: 10.1259/bjr.20150097. Epub 2015 Apr 22.

31.

Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies.

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR.

Crit Rev Oncol Hematol. 2015 Jul;95(1):114-24. doi: 10.1016/j.critrevonc.2015.01.003. Epub 2015 Jan 12.

PMID:
25624177
32.

Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E.

Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Review.

33.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D.

J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review.

PMID:
25347767
34.

Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K.

PLoS One. 2014 Feb 25;9(2):e89750. doi: 10.1371/journal.pone.0089750. eCollection 2014.

35.

[Cardioprotective treatment during adjuvant cancer therapy].

Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T.

Tidsskr Nor Laegeforen. 2013 Sep 17;133(17):1832-6. doi: 10.4045/tidsskr.12.1514. Review. Norwegian.

36.

Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi: 10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10.

PMID:
24035332
37.

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J.

PLoS One. 2013 Aug 30;8(8):e72692. doi: 10.1371/journal.pone.0072692. eCollection 2013.

38.

Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience.

Ree AH, Hollywood D.

Radiother Oncol. 2013 Jul;108(1):3-16. doi: 10.1016/j.radonc.2013.06.007. Epub 2013 Jul 3. Review.

39.

Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.

Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH.

PLoS One. 2013 May 10;8(5):e63723. doi: 10.1371/journal.pone.0063723. Print 2013.

40.

Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer.

Hole KH, Larsen SG, Grøholt KK, Giercksky KE, Ree AH.

Radiother Oncol. 2013 May;107(2):178-83. doi: 10.1016/j.radonc.2013.03.017. Epub 2013 Apr 17.

PMID:
23602370
41.

Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer.

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K.

PLoS One. 2012;7(11):e50806. doi: 10.1371/journal.pone.0050806. Epub 2012 Nov 30.

42.

Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial.

Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T.

Cardiology. 2012;123(4):240-7. doi: 10.1159/000343622. Epub 2012 Nov 30.

43.

Individualised treatment of metastatic cancer.

Ree AH.

Tidsskr Nor Laegeforen. 2012 Nov 12;132(21):2358-9. doi: 10.4045/tidsskr.12.1130. English, Norwegian. No abstract available.

44.

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K.

Radiat Oncol. 2012 Sep 27;7:165. doi: 10.1186/1748-717X-7-165.

45.

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR.

Radiat Oncol. 2012 May 23;7:75. doi: 10.1186/1748-717X-7-75.

46.

Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E.

BMC Cancer. 2011 Oct 20;11:455. doi: 10.1186/1471-2407-11-455.

47.

Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.

Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH.

Angiogenesis. 2011 Dec;14(4):481-9. doi: 10.1007/s10456-011-9231-3. Epub 2011 Aug 11.

48.

Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.

Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR.

Radiat Oncol. 2011 Jun 8;6:65. doi: 10.1186/1748-717X-6-65.

49.

Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH.

Radiat Oncol. 2011 Apr 8;6:33. doi: 10.1186/1748-717X-6-33.

50.

Supplemental Content

Support Center